

Title (en)

SUSTAINED-RELEASE FORMULATIONS FOR TREATING CNS-MEDIATED DISORDERS

Title (de)

FORMULIERUNGEN MIT VERZÖGERTER FREISETZUNG ZUR BEHANDLUNG VON ZNS-VERMITTELTEN STÖRUNGEN

Title (fr)

COMPOSITIONS A LIBERATION PROLONGEE POUR LE TRAITEMENT DE PATHOLOGIES INDUITES PAR LE SYSTEME NERVEUX CENTRAL

Publication

EP 1225888 A2 20020731 (EN)

Application

EP 00982701 A 20001019

Priority

- US 0041267 W 20001019
- US 16021099 P 19991019

Abstract (en)

[origin: WO0128516A2] Sustained-release compositions for delivering therapeutic concentrations of isovaleramide, isovaleric acid, and certain structurally related compounds are provided for the treatment for a variety of pathological conditions, including epilepsy and spasticity, which are ameliorated by effecting a modulation of CNS activity. The ability of the compositions to sustain relatively constant levels of the drug at a therapeutic dose in the serum for extended periods of time enables a once or twice daily administration schedule.

IPC 1-7

A61K 31/195; **A61K 31/16**; **A61K 31/19**; **A61K 31/60**; **A61K 31/22**; **A61K 31/165**; **A61K 31/18**; **A61K 31/255**; **A61K 31/27**; **A61K 9/28**; **A61K 9/50**

IPC 8 full level

A61K 9/16 (2006.01); **A61K 9/22** (2006.01); **A61K 9/28** (2006.01); **A61K 9/36** (2006.01); **A61K 9/50** (2006.01); **A61K 9/52** (2006.01); **A61K 31/16** (2006.01); **A61K 31/18** (2006.01); **A61K 31/19** (2006.01); **A61K 31/22** (2006.01); **A61K 31/255** (2006.01); **A61K 31/27** (2006.01); **A61K 47/30** (2006.01); **A61K 47/36** (2006.01); **A61K 47/38** (2006.01); **A61P 15/08** (2006.01); **A61P 17/02** (2006.01); **A61P 25/00** (2006.01); **A61P 25/02** (2006.01); **A61P 25/04** (2006.01); **A61P 25/06** (2006.01); **A61P 25/08** (2006.01); **A61P 25/18** (2006.01); **A61P 25/20** (2006.01); **A61P 25/22** (2006.01); **A61P 25/30** (2006.01); **A61P 25/32** (2006.01); **A61P 25/34** (2006.01); **A61K 9/20** (2006.01)

CPC (source: EP)

A61K 9/2866 (2013.01); **A61K 9/5042** (2013.01); **A61K 31/16** (2013.01); **A61K 31/18** (2013.01); **A61K 31/19** (2013.01); **A61K 31/255** (2013.01); **A61K 31/27** (2013.01); **A61P 15/08** (2017.12); **A61P 17/02** (2017.12); **A61P 25/00** (2017.12); **A61P 25/02** (2017.12); **A61P 25/04** (2017.12); **A61P 25/06** (2017.12); **A61P 25/08** (2017.12); **A61P 25/18** (2017.12); **A61P 25/20** (2017.12); **A61P 25/22** (2017.12); **A61P 25/30** (2017.12); **A61P 25/32** (2017.12); **A61P 25/34** (2017.12); **A61K 9/205** (2013.01)

Citation (search report)

See references of WO 0128516A2

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 0128516 A2 20010426; **WO 0128516 A3 20020221**; AU 1969501 A 20010430; AU 780505 B2 20050324; CA 2387819 A1 20010426; CN 1409630 A 20030409; EP 1225888 A2 20020731; JP 2003512311 A 20030402; MX PA02003976 A 20030925; TW I252761 B 20060411

DOCDB simple family (application)

US 0041267 W 20001019; AU 1969501 A 20001019; CA 2387819 A 20001019; CN 00817059 A 20001019; EP 00982701 A 20001019; JP 2001531111 A 20001019; MX PA02003976 A 20001019; TW 90108635 A 20010411